These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 13563875)

  • 1. Quantitative studies of the properdin-complement system. III. Kinetics of the reaction between C'3 and the properdin-zymosan complex.
    LEON MA
    J Immunol; 1958 Jul; 81(1):23-8. PubMed ID: 13563875
    [No Abstract]   [Full Text] [Related]  

  • 2. Quantitative studies on the properdin-complement system. II. Kinetics of the reaction between properdin and zymosan.
    LEON MA
    J Exp Med; 1957 May; 105(5):403-15. PubMed ID: 13428911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative studies on the properdin-complement system.
    LEON MA
    J Exp Med; 1956 Mar; 103(3):285-93. PubMed ID: 13295486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Methodical and clinical research on the properdin system. II. Research on the behavior of the serum properdin and the C'3 components after gynecological operations].
    SCHUMACHER G; EL HABASH E; SCHLUMBERGER HD
    Arch Gynakol; 1961; 196():167-79. PubMed ID: 13748953
    [No Abstract]   [Full Text] [Related]  

  • 5. EVIDENCE FOR IMMUNOLOGICAL SPECIFICITY OF THE PROPERDIN SYSTEM; DEMONSTRATION, ISOLATION AND PROPERTIES OF A SERUM FACTOR WHICH INTERACTS WITH ZYMOSAN AND OTHER POLYSACCHARIDES AT 0 DEGREES CENTIGRADE.
    BLUM L
    J Immunol; 1964 Jan; 92():61-72. PubMed ID: 14139548
    [No Abstract]   [Full Text] [Related]  

  • 6. The reaction of zymosan with the properdin system: isolation of purified factor D from guinea pig serum and study of its reaction characteristics.
    Brade V; Nicholson A; Lee GD; Mayer MM
    J Immunol; 1974 May; 112(5):1845-54. PubMed ID: 4818461
    [No Abstract]   [Full Text] [Related]  

  • 7. Kinetic studies of the formation of the properdin system enzymes on zymosan: evidence that nascent C3b controls the rate of assembly.
    Nicholson A; Brade V; Lee GD; Shin HS; Mayer MM
    J Immunol; 1974 Mar; 112(3):1115-23. PubMed ID: 4811964
    [No Abstract]   [Full Text] [Related]  

  • 8. Replacement of magnesium by cobalt and manganese in the interactions of the properdin system with bacteria and with zymosan.
    WARDLAW AC; BLUM L; PILLEMER L
    J Immunol; 1958 Jul; 81(1):43-7. PubMed ID: 13563878
    [No Abstract]   [Full Text] [Related]  

  • 9. The properdin system and immunity. VII. Alterations in properdin levels and resistance to infection in mice following the administration of tissue polysaccharides.
    PILLEMER L; LANDY M; SHEAR MJ
    J Exp Med; 1957 Jul; 106(1):99-110. PubMed ID: 13439118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Modification of complement factors and their inhibitors during meningococcal sepsis (author's transl)].
    Blanco A; Solís P; Alvarez Guisasola FJ; Valbuena C; Gómez C; Prieto P; Ruíz C
    An Esp Pediatr; 1980 Aug; 13(8):679-88. PubMed ID: 7436149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An alternative mechanism for the properdin system.
    NELSON RA
    J Exp Med; 1958 Oct; 108(4):515-35. PubMed ID: 13575682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The requirement for magnesium ions in the inactivation of the third component of human complement (C'3) by insoluble residues of yeast cells (zymosan).
    PILLEMER L; BLUM L; PENSKY J; LEPOW IH
    J Immunol; 1953 Nov; 71(5):331-8. PubMed ID: 13118169
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibitor of human C3 associated with preparations of C3 dissociated from C3-zymosan complex.
    Blum L
    J Immunol; 1969 Nov; 103(5):1116-24. PubMed ID: 5350971
    [No Abstract]   [Full Text] [Related]  

  • 14. Functional relationship of factor B in the properdin system to C3 proactivator of human serum.
    Goodkofsky I; Lepow IH
    J Immunol; 1971 Oct; 107(4):1200-4. PubMed ID: 5093780
    [No Abstract]   [Full Text] [Related]  

  • 15. Research on the properdin system. I. Inactivation of the third complement component through zymosan on inulin.
    HEISE ER
    Klin Wochenschr; 1958 Jan; 36(2):88-9. PubMed ID: 13540126
    [No Abstract]   [Full Text] [Related]  

  • 16. Formation of the C3-cleaving properdin enzyme on zymosan. Demonstration that factor D is replaceable by proteolytic enzymes.
    Brade V; Nicholson A; Bitter-Suermann D; Hadding U
    J Immunol; 1974 Dec; 113(6):1735-43. PubMed ID: 4279261
    [No Abstract]   [Full Text] [Related]  

  • 17. The requirement for a hydrazine-sensitive serum factor and heat-labile serum factors in the inactivation of human C'3 by zymosan.
    PILLEMER L; LEPOW IH; BLUM L
    J Immunol; 1953 Nov; 71(5):339-45. PubMed ID: 13118170
    [No Abstract]   [Full Text] [Related]  

  • 18. [Interrelations of zymosan, properdin & tumors. III. Behavior of the properdin level in benzopyrene sarcoma-bearing rats treated with zymosan].
    FUMAROLA D; MODICA F
    Tumori; 1959; 45(1):46-53. PubMed ID: 13659609
    [No Abstract]   [Full Text] [Related]  

  • 19. Studies of the inactivation of phage by the properdin system. I. Evidence for complement, properdin and magnesium requirements.
    BARLOW JL; VAN VUNAKIS H; LEVINE L
    J Immunol; 1958 May; 80(5):339-48. PubMed ID: 13539378
    [No Abstract]   [Full Text] [Related]  

  • 20. Studies on the mechanism of properdin--zymosan reaction. The role of polysaccharide structure in combination with properdin.
    CSEH G; SZABO I
    Acta Microbiol Acad Sci Hung; 1961; 8():181-7. PubMed ID: 13718704
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.